Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AOC3 | Q16853 | 3/20 | 0.57 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.55 |
| ▸ | CA2 | P00918 | 6/20 | 0.50 |
| ▸ | CA1 | P00915 | 3/20 | 0.47 |
| ▸ | CA9 | Q16790 | 3/20 | 0.47 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.46 |
| ▸ | MMP3 | P08254 | 1/20 | 0.46 |
| ▸ | CA5A | P35218 | 1/20 | 0.45 |
| ▸ | CA12 | O43570 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13184564 | 0.82 | TAAR1 (0.57) | AOC3TAAR1SIGMAR1MMP3 | |
| SCHEMBL25477196 | 0.81 | TAAR1 (0.55) | AOC3TAAR1SIGMAR1MMP3 | |
| SCHEMBL6335172 | 0.81 | TAAR1 (0.55) | AOC3TAAR1SIGMAR1MMP3 | |
| SCHEMBL1243447 | 0.80 | CA2 (0.64) | AOC3CA2CA1CA9CA5A | |
| SCHEMBL15754217 | 0.80 | CA2 (0.64) | AOC3TAAR1CA2CA1CA9 | |
| SCHEMBL411162 | 0.79 | HDAC3 (0.55) | AOC3TAAR1 | |
| SCHEMBL12133562 | 0.79 | MMP3 (0.55) | AOC3TAAR1CA2CA1CA9 | |
| SCHEMBL27386707 | 0.78 | TSHR (0.53) | AOC3TAAR1SIGMAR1MMP3 | |
| Phenethylamine SCHEMBL2928784 | 0.77 | HTR2A (0.61) | AOC3TAAR1CA2CA1CA9 | |
| SCHEMBL7302947 | 0.76 | MMP3 (0.59) | AOC3TAAR1CA2CA1CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8299021-B2 | Macrocyclic inhibitors of hepatitis C virus replication | INTERMUNE, INC. (US) | 2012-10-30 | — | — | US | disclosed |
| US-8299021-B2 | Macrocyclic inhibitors of hepatitis C virus replication | INTERMUNE, INC. (US) | 2012-10-30 | — | — | US | disclosed |
| US-8299021-B2 | Macrocyclic inhibitors of hepatitis C virus replication | INTERMUNE, INC. (US) | 2012-10-30 | — | — | US | disclosed |
| US-20120208995-A1 | NOVEL MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS REPLICATION | ARRAY BIOPHARMA, INC. (US) | 2012-08-16 | — | — | US | disclosed |
| US-20120208995-A1 | NOVEL MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS REPLICATION | ARRAY BIOPHARMA, INC. (US) | 2012-08-16 | — | — | US | disclosed |
| US-20120208995-A1 | NOVEL MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS REPLICATION | ARRAY BIOPHARMA, INC. (US) | 2012-08-16 | — | — | US | disclosed |
| EP-2305698-A2 | Macrocyclic inhibitors of Hepatitis C virus replication | Intermune, Inc. (US) | 2011-04-06 | — | — | EP | disclosed |
| EP-2305696-A2 | Macrocyclic inhibitors of Hepatitis C virus replication | Intermune, Inc. (US) | 2011-04-06 | — | — | EP | disclosed |
| EP-2305698-A2 | Macrocyclic inhibitors of Hepatitis C virus replication | Intermune, Inc. (US) | 2011-04-06 | — | — | EP | disclosed |
| EP-2305696-A2 | Macrocyclic inhibitors of Hepatitis C virus replication | Intermune, Inc. (US) | 2011-04-06 | — | — | EP | disclosed |
| US-20090169510-A1 | NOVEL MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS REPLICATION | INTERMUNE, INC. (US) | 2009-07-02 | — | — | US | disclosed |
| US-20090169510-A1 | NOVEL MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS REPLICATION | INTERMUNE, INC. (US) | 2009-07-02 | — | — | US | disclosed |
| US-20090148407-A1 | Novel Macrocyclic Inhibitors of Hepatitis C Virus Replication | INTERMUNE, INC. (US) | 2009-06-11 | — | — | US | disclosed |
| US-20090148407-A1 | Novel Macrocyclic Inhibitors of Hepatitis C Virus Replication | INTERMUNE, INC. (US) | 2009-06-11 | — | — | US | disclosed |
| US-20090148407-A1 | Novel Macrocyclic Inhibitors of Hepatitis C Virus Replication | INTERMUNE, INC. (US) | 2009-06-11 | — | — | US | disclosed |
| EP-1924594-A2 | NOVEL MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS REPLICATION | Intermune, Inc. (US) | 2008-05-28 | — | — | EP | disclosed |
| US-20070054842-A1 | Novel macrocyclic inhibitors of hepatitis C virus replication | ARRAY BIOPHARMA, INC. | 2007-03-08 | — | — | US | disclosed |
| US-20070054842-A1 | Novel macrocyclic inhibitors of hepatitis C virus replication | ARRAY BIOPHARMA, INC. | 2007-03-08 | — | — | US | disclosed |
| US-20070054842-A1 | Novel macrocyclic inhibitors of hepatitis C virus replication | ARRAY BIOPHARMA, INC. | 2007-03-08 | — | — | US | disclosed |
| WO-2007015824-A2 | NOVEL MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS REPLICATION | INTERMUNE, INC. (US) | 2007-02-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090169510-A1 | NOVEL MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS REPLICATION | EIF2AK2, HAVCR2, HCCS | AOC3 3451/4885TAAR1 4747/4885CA2 4474/4885 |
| US-20070054842-A1 | Novel macrocyclic inhibitors of hepatitis C virus replication | EIF2AK2, HAVCR2, HCCS | AOC3 3451/4885TAAR1 4747/4885CA2 4474/4885 |
| US-20120208995-A1 | NOVEL MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS REPLICATION | EIF2AK2, HAVCR2, HCCS | AOC3 3451/4885TAAR1 4747/4885CA2 4474/4885 |
| US-20090148407-A1 | Novel Macrocyclic Inhibitors of Hepatitis C Virus Replication | EIF2AK2, HAVCR2, HCCS | AOC3 3196/4885TAAR1 4742/4885CA2 4462/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.